Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the effect of adalimumab in pediatric uveitis and subsequent changes in anterior chamber inflammationfollowing the inactivation of uveitis. Methods: In this retrospective study, patients with noninfectious uveitis younger than 18 years of age who were treatedwith adalimumab for more than 12 months were included. The rate of complete suppression and the relapse in anteriorchamber inflammation following the initiation of adalimumab therapy were evaluated using anterior chamber cell score andlaser flare photometry (LFP) values, if available. Changes in visual acuity and the sparing effect of topical steroid agents werealso evaluated. Results: Among 22 eyes of 12 pediatric uveitis patients enrolled, 13 eyes were associated with juvenile idiopathic arthritisand nine eyes had idiopathic uveitis. The mean ± standard deviation age was 10.2 ± 3.6 years. Types of uveitis included anterioruveitis (n = 17) and panuveitis (n = 5). Quiescence was observed in 14 eyes (63.6%) at 3 months and in 21 eyes (95.5%) at12 months after initiation, respectively. After achieving inactive uveitis, uveitis relapsed in two eyes at 6 months, even withadalimumab treatment. In 11 eyes, anterior chamber showed 0.5+ cell scores during the rest of the follow-up period and oneof those eyes met the criteria for the relapse based on LFP values. The dosage of topical steroids decreased significantly at3, 9, and 12 months after the initiation of therapy (p ≤ 0.05). Visual acuity did not show improvement. There were no severeadverse effects of anti-tumor necrosis factor-α treatment reported. Conclusions: In this study, adalimumab achieved a quiescent state in most eyes with pediatric noninfectious uveitis for 12months with a relapse rate of 9.5%. LFP values together with the anterior chamber cell score can be utilized to monitor theimprovement or relapse in anterior chamber inflammation in pediatric noninfectious uveitis.
Abstract
Purpose: To evaluate the effect of adalimumab in pediatric uveitis and subsequent changes in anterior chamber inflammationfollowing the inactivation of uveitis. Methods: In this retrospective study, patients with noninfectious uveitis younger than 18 years of age who were treatedwith adalimumab for more than 12 months were included. The rate of complete suppression and the relapse in anteriorchamber inflammation following the initiation of adalimumab therapy were evaluated using anterior chamber cell score andlaser flare photometry (LFP) values, if available. Changes in visual acuity and the sparing effect of topical steroid agents werealso evaluated. Results: Among 22 eyes of 12 pediatric uveitis patients enrolled, 13 eyes were associated with juvenile idiopathic arthritisand nine eyes had idiopathic uveitis. The mean ± standard deviation age was 10.2 ± 3.6 years. Types of uveitis included anterioruveitis (n = 17) and panuveitis (n = 5). Quiescence was observed in 14 eyes (63.6%) at 3 months and in 21 eyes (95.5%) at12 months after initiation, respectively. After achieving inactive uveitis, uveitis relapsed in two eyes at 6 months, even withadalimumab treatment. In 11 eyes, anterior chamber showed 0.5+ cell scores during the rest of the follow-up period and oneof those eyes met the criteria for the relapse based on LFP values. The dosage of topical steroids decreased significantly at3, 9, and 12 months after the initiation of therapy (p ≤ 0.05). Visual acuity did not show improvement. There were no severeadverse effects of anti-tumor necrosis factor-α treatment reported. Conclusions: In this study, adalimumab achieved a quiescent state in most eyes with pediatric noninfectious uveitis for 12months with a relapse rate of 9.5%. LFP values together with the anterior chamber cell score can be utilized to monitor theimprovement or relapse in anterior chamber inflammation in pediatric noninfectious uveitis.
참고문헌 (21)
- Paivonsalo-Hietanen T, "Uveitis in children : population-based study in Finland", Acta Ophthalmol Scand, 78, pp.84~88 (2000)
- Zierhut M, "Uveitis in children", Int Ophthalmol Clin, 45, pp.135~156 (2005)
- Cann M, "Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy", Pediatr Rheumatol Online J, 16, pp.51~ (2018)
- Smith JA, "Epidemiology and course of disease in childhood uveitis", Ophthalmology, 116, pp.1544~1551 (2009)
- Reiff A, "Etanercept therapy in children with treatment-resistant uveitis", Arthritis Rheum, 44, pp.1411~1415 (2001)
- Carrasco R, "Biologic agents for the treatment of juvenile rheumatoid arthritis : current status", Paediatr Drugs, 6, pp.137~146 (2004)
- Ramanan AV, "Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis", N Engl J Med, 376, pp.1637~1646 (2017)
- Jabs DA, "Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop", Am J Ophthalmol, 140, pp.509~516 (2005)
- Herbort CP, "The importance of quantitative measurement methods for uveitis : laser flare photometry endorsed in Europe while neglected in Japan where the technology measuring quantitatively intraocular inflammation was developed", Int Ophthalmol, 37, pp.469~473 (2017)
- Heiligenhaus A, "Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood", Arthritis Care Res(Hoboken), 64, pp.1365~1372 (2012)
- Bernasconi O, "Sensitivity of laser flare photometry compared to slit-lamp cell evaluation in monitoring anterior chamber inflammation in uveitis", Int Ophthalmol, 30, pp.495~500 (2010)
- Quartier P, "ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis", Ann Rheum Dis, 77, pp.1003~1011 (2018)
- Herbort CP, "Use of laser flare photometry to assess and monitor inflammation in uveitis", Ophthalmology, 104, pp.64~71 (1997)
- Sawa M, "New quantitative method to determine protein concentration and cell number in aqueous in vivo", Jpn J Ophthalmol, 32, pp.132~142 (1988)
- el-Maghraby A, "Reproducibility and validity of laser flare", cell meter measurements as an objective method of assessing intraocular inflammation, 1992, pp.110, 960~962
- Tugal-Tutkun I, "Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation", Int Ophthalmol, 30, pp.453~464 (2010)
- Deitch I, "The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies", Graefes Arch Clin Exp Ophthalmol, 256, pp.801~808 (2018)
- Castiblanco C, "Treatment of pediatric uveitis with adalimumab : the MERSI experience", J AAPOS, 20, pp.145~147 (2016)
- Ardoin SP, "Infliximab to treat chronic noninfectious uveitis in children : retrospective case series with long-term follow-up", Am J Ophthalmol, 144, pp.844~849 (2007)
- Sen ES, "Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease: a case cohort interventional study", Rheumatology(Oxford), 51, pp.2199~2203 (2012)
- Antoni C, "Side effects of anti-TNF therapy : current knowledge", Clin Exp Rheumatol, 20, pp.S152~S157 (2002)